Therefore, although the pathway from IL-34 to Sox13 and downstream adverse phenotypes has been observed in AML, the molecular mechanisms including how IL-34 regulates the expression of Sox13, the downstream events of Sox13 leading to enhanced proliferation, more LSCs and subcutaneous infiltration have not been elucidated and deserve further exploration. This evidence concerns the gene IL34 and acute myeloid leukemia.